Inclusion Criteria:

1. Aged 35-80 years;
2. Stroke duration within 2 weeks to 6 months post-onset;
3. Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score < 26;
4. Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.);
5. No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study;
6. Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.

Exclusion Criteria:

1. Unstable vital signs or life-threatening comorbidities;
2. Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.);
3. History of epilepsy or epileptic seizures;
4. Pregnant or lactating women;
5. Concurrent use of other medications affecting cognitive function;
6. Allergy to the study intervention device or history of serious adverse reactions;
7. Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.);
8. Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.